Ectopic model (mouse model)

db/db experimental model that has a mutation in the leptin gene that causes obesity and consequently generates type 2 diabetes. Early non-proliferative diabetic retinopathy (DR) is a complication of diabetes. This model spontaneously develops hyperglycemia and obesity at 4 weeks of life, generating a pheNoype similar to human DR patients with reactive gliosis and neuronal apoptosis. Diabetic macular edema is the leading cause of poor visual acuity in type 2 diabetes

The low-dose streptozotocin model has been widely used for years in numerous publications with excellent results. The main advantage of drug delivery-based models is that the degree of β-cell disruption can be regulated according to the dose of toxin administered. This diabetic rat constitutes a good model because it generates vascular dysfunction and retinal neurodegeneration similar to human pathogenesis and allows obtaining sufficient amounts of retinal RNA or protein for experimental procedures. 1 dose of 65 mg/kg of STZ solution intraperitoneally. A week after stabilization, weight and blood glucose are measured. If the injected rats have a blood glucose level of > 250 mg/dl, they are considered diabetic.

This model exhibits servere obesity and altered glucose homeostasis (glucose intolerance and insulin resistance) after being fed with a high fat diet (45% Kcal from fat) or very high fat diet (60 % kcal from fat).

Model generated by Implantation of subcutaneous isoproterenol release pump

Model generated by Implantation of subcutaneous angiotensin II release pump

The DKO rd8 is obtained by crossing the C57BL/6NJ strain (homozygous for the Crb1rd8 mutation, the B6.129S4-*Ccl2tm1Rol*/J strain (homozygous for the Ccl2tm1Rol (Ccl2-/-) mutation), and the B6. 129P-*Cx3cr1tm1Litt*/J strain (homozygous for the Cx3cr1tm1Litt (Cx3cr1-/-) mutation). Availability: Cryopreserved

EAE model presents both clinical and histopathological characteristics that are very similar to those of the human disease and it is widely used for drug screening or therapeutic approaches. C57BL6/J strain immunized with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG 35-55) develops a chronic clinical course.

EAE model presents both clinical and histopathological characteristics that are very similar to those of the human disease and it is widely used for drug screening or therapeutic approaches. NOD strain immunized with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG 35-55) develops a chronic progressive clinical course.

EAE model presents both clinical and histopathological characteristics that are very similar to those of the human disease and it is widely used for drug screening or therapeutic approaches. SJL/J strain immunized with proteolipidic protein peptide 139-151 (PLP139-151) develops a relapsing-remitting clinical course.